title: Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations.
abstract: BACKGROUND
  Patients with heart disease are frequently maintained on a regimen of aspirin because of its ability to decrease thrombotic complications and reduce the prevalence of unstable angina and myocardial infarction. Aspirin-induced platelet acetylation also increases bleeding caused by impairment of platelet function during cardiac surgery.
  
  
  METHODS
  Between October 1990 and November 1991 this double-blind, randomized, placebo-controlled, parallel group interventional study examined the efficacy of high-dose aprotinin administration (up to 7 million KIU) to decrease blood loss and transfusion requirements in patients receiving aspirin within 48 hours of undergoing coronary bypass or valvular heart operations. Primary outcome measures in this study were total volume of blood loss (intraoperative blood loss plus postoperative chest tube drainage) and volume of transfusion during hospitalization.
  
  
  RESULTS
  Patients treated with aprotinin (n = 29) had significantly lower total blood loss (1409 +/- 232 ml versus 2765 +/- 248 ml; p = 0.0002), intraoperative blood loss (503 +/- 53 ml versus 1055 +/- 199 ml; p = 0.0001), postoperative blood loss (906 +/- 204 ml versus 1710 +/- 202 ml; p = 0.0074), and prevalence of transfusion (59% versus 88% of patients; p = 0.016) than the placebo group (n = 25). The prevalence of complications including myocardial infarction was similar in the two groups.
  
  
  CONCLUSIONS
  High-dose aprotinin significantly reduces blood loss and red blood cell transfusions in patients receiving aspirin who undergo cardiac operations.
authors.affiliation: Department of Anaesthesia, University Hospital, University of Western Ontario, London, Canada.
authors.forename: J M
authors.initials: JM
authors.lastname: Murkin
authors.forename: J
authors.initials: J
authors.lastname: Lux
authors.forename: N A
authors.initials: NA
authors.lastname: Shannon
authors.forename: G M
authors.initials: GM
authors.lastname: Guiraudon
authors.forename: A H
authors.initials: AH
authors.lastname: Menkis
authors.forename: F N
authors.initials: FN
authors.lastname: McKenzie
authors.forename: R J
authors.initials: RJ
authors.lastname: Novick
mesh_terms: D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D001810:Blood Volume; D006348:Cardiac Surgical Procedures; D004311:Double-Blind Method; D005260:Female; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D011183:Postoperative Complications
chemical_list: D007611:Aprotinin; D001241:Aspirin